Critically analyse the evolution of medical device regulation in India from the Drugs and Cosmetics Act, 1940 to the Medical Devices Rules, 2017.

Medical devices in India were long regulated as "drugs" under the Drugs and Cosmetics Act, 1940 [1] — a statute framed for chemical molecules, not engineered products. The Medical Devices Rules, 2017 [2] marked a shift to a risk-based, device-specific regime; the transition, however, remains incomplete.

Trajectory of evolution

• Regulation by omission (1940–2005): only devices notified as drugs under the parent Act came under control; most devices stayed outside any framework [1].
• Piecemeal notification (2005–2016): a short list — syringes, catheters, stents, implants — was regulated through pharma-style licensing under the Drugs and Cosmetics Rules, 1945, ill-suited to engineered goods.
• Institutional critique (2012): the 59th Parliamentary Standing Committee report on CDSCO exposed understaffing, weak approval scrutiny and industry proximity in the regulator [3].
• Dedicated framework (2017): the MDR, notified 31 January 2017 and effective 1 January 2018, introduced four-tier risk classification (Class A–D), Notified Bodies and defined licensing and clinical-investigation pathways [2].
• Consolidation (post-2017): the National Medical Devices Policy, 2023, with PLI and Medical Device Parks, added an industrial-policy dimension [4]; 2026 proposals seek to remove duplicate loan licences for outsourced sterilisation and add the EU to recognised jurisdictions for trial waivers [5].

Critical appraisal

• Gains: risk-proportionate, globally harmonised classification; predictable timelines; deregulation balanced by traceability, as the sterilising facility's licence number must appear on the label [5].
• Gaps: devices remain delegated legislation under a 1940 drugs statute, with no standalone Act [1]; CDSCO's capacity deficit and thin testing-lab and Notified Body networks persist [3]; reliance on foreign approvals for waivers risks limited validation in Indian populations [5]; import dependence and post-market surveillance remain weak links the 2023 Policy still seeks to address [4].

The journey from incidental to institutional regulation is real but unfinished. A standalone medical devices statute, a strengthened CDSCO and robust adverse-event surveillance would let ease of doing business and the Article 21 guarantee of patient safety advance together.